Tandem Diabetes Care Reports 5.4% Revenue Growth in Q2 2026

Tandem Diabetes Care, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $254.6 million, a 5.4% increase from $240.7 million in the same period last year. For the first half of 2026, the company generated $501.8 million in sales, up from $475.1 million in the first half of 2025. The growth in revenue was attributed to improved pricing, a favorable channel mix, and increased pump volumes, despite facing inventory constraints from a key supplier that impacted supply sales.

The company's gross profit for the second quarter was $144.8 million, resulting in a gross margin of 57%, compared to 52% in the prior year. This increase in gross margin was primarily driven by favorable pricing dynamics and operational efficiencies. Operating expenses decreased to $158.6 million from $177.7 million year-over-year, largely due to the absence of one-time litigation and settlement charges that had impacted the previous year's results. The company reported an operating loss of $13.8 million, a significant improvement from a loss of $51.8 million in the same quarter of 2025.

Tandem's customer base continues to expand, with over 33,000 pumps shipped worldwide in the second quarter. The company has also seen a shift in its sales strategy, moving towards a pharmacy benefit reimbursement model, which has begun to show positive results. Sales through the pharmacy channel accounted for 10% of U.S. sales in the second quarter, up from 3% in the same period last year. The company shipped more than 22,000 pumps in the U.S. during the quarter, reflecting a growing adoption of its products.

In terms of financial position, Tandem reported total assets of $1.15 billion as of June 30, 2026, up from $881.1 million at the end of 2025. The increase was driven by a rise in short-term investments and cash equivalents, which totaled $456 million. However, the company also reported a net loss of $21.2 million for the quarter, an improvement from a loss of $52.4 million in the prior year. The accumulated deficit as of June 30, 2026, stood at $1.29 billion.

Looking ahead, Tandem Diabetes Care is focused on expanding its product offerings and enhancing its market presence. The company is actively pursuing regulatory approvals for new product features, including a tubeless capability for its Tandem Mobi pump, and aims to leverage its innovative technology to capture a larger share of the diabetes management market. The company remains optimistic about its growth trajectory, although it acknowledges the potential challenges posed by market competition and regulatory changes.